N/A
Completed N=1,377
ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking
Source: ClinicalTrials.gov NCT00808015 ↗Enrolled (actual)
1,377
Serious AEs
0.8%
Results posted
Jul 2011
Primary outcomePrimary: Percentage of Participants With Smoking Abstinence at Week 12 — 46.40 percentage of participants
Summary
The purpose of this study is to describe the characteristics of the smoker who wants to quit and his/her treating physician, in addition to determine the safety and effectiveness of Champix in the real-world setting of smokers in routine clinical practice.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With Smoking Abstinence at Week 12 |
46.40 | — |
| SECONDARY Percentage of Participants With Smoking Abstinence Before Last Observed Study Visit |
50.30 | — |
| SECONDARY Percentage of Participants With Smoking Abstinence Status From Week 3 to Week 11 |
31.3; 38.2; 45.4; 47.8; 49.5; 51.6 | — |
| SECONDARY CO Level at Last Observed Study Visit |
4.1 | — |
| SECONDARY Average Weekly Number of Cigarettes Smoked at Last Observed Study Visit |
10.0 | — |
Eligibility Criteria
Inclusion Criteria
- All patients enrolled should meet the usual prescribing criteria for Champix® as per the local product information and should be entered into the trial at the investigator's discretion
Exclusion Criteria
- All patients enrolled should meet the usual prescribing criteria for Champix® as per the local product information and should be entered into the trial at the investigator's discretion
Data sourced from ClinicalTrials.gov (NCT00808015). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.